Results Wire: US FDA Advisory Committee Gives Input on Communicating the Fetal Effects of Methadone or Buprenorphine for Opioid Addiction – JUN 8-9, 2015 (RCAC)
On Monday and Tuesday, June 8-9, 2015, the Risk Communications Advisory Committee (RCAC) discussed and advised the FDA on approaches to communicating information about fetal effects in product labeling for methadone or buprenorphine maintenance therapy for opioid addiction, and about the maternal benefits and risks of treatment, to best enable patients and healthcare providers to make informed decisions about the use of these drugs during pregnancy.